171 related articles for article (PubMed ID: 37735552)
1. The role of T cells and myeloid-derived suppressor cells in refractory immune thrombocytopenia.
Yazdanbakhsh K; Provan D; Semple JW
Br J Haematol; 2023 Oct; 203(1):54-61. PubMed ID: 37735552
[TBL] [Abstract][Full Text] [Related]
2. Circulating myeloid-derived suppressor cells predict disease activity and treatment response in patients with immune thrombocytopenia.
Zhou J; Zhou Y; Wen J; Sun X; Zhang X
Braz J Med Biol Res; 2017 Feb; 50(2):e5637. PubMed ID: 28225866
[TBL] [Abstract][Full Text] [Related]
3. High-dose dexamethasone corrects impaired myeloid-derived suppressor cell function via Ets1 in immune thrombocytopenia.
Hou Y; Feng Q; Xu M; Li GS; Liu XN; Sheng Z; Zhou H; Ma J; Wei Y; Sun YX; Yu YY; Qiu JH; Shao LL; Liu XG; Hou M; Peng J
Blood; 2016 Mar; 127(12):1587-97. PubMed ID: 26744458
[TBL] [Abstract][Full Text] [Related]
4. Complement activation negatively affects the platelet response to thrombopoietin receptor agonists in patients with immune thrombocytopenia: a prospective cohort study.
Åkesson A; Bussel JB; Martin M; Blom AM; Klintman J; Ghanima W; Zetterberg E; Garabet L
Platelets; 2023 Dec; 34(1):2159019. PubMed ID: 36636835
[TBL] [Abstract][Full Text] [Related]
5. Low-dose decitabine modulates myeloid-derived suppressor cell fitness via LKB1 in immune thrombocytopenia.
Ni X; Wang L; Wang H; Yu T; Xie J; Li G; Liu Y; Zhou H; Xu M; Hou M; Peng J; Hou Y
Blood; 2022 Dec; 140(26):2818-2834. PubMed ID: 36037415
[TBL] [Abstract][Full Text] [Related]
6. Pathogenesis of immune thrombocytopenia.
Audia S; Mahévas M; Samson M; Godeau B; Bonnotte B
Autoimmun Rev; 2017 Jun; 16(6):620-632. PubMed ID: 28428120
[TBL] [Abstract][Full Text] [Related]
7. Glucocorticoid receptor modulates myeloid-derived suppressor cell function via mitochondrial metabolism in immune thrombocytopenia.
Hou Y; Xie J; Wang S; Li D; Wang L; Wang H; Ni X; Leng S; Li G; Hou M; Peng J
Cell Mol Immunol; 2022 Jul; 19(7):764-776. PubMed ID: 35414712
[TBL] [Abstract][Full Text] [Related]
8. [Recent advances in pathophysiology and treatment of immune thrombocytopenia].
Kashiwagi H; Tomiyama Y
Rinsho Ketsueki; 2015 Feb; 56(2):177-84. PubMed ID: 25765798
[TBL] [Abstract][Full Text] [Related]
9. Distinct alterations of CD68
Shao X; Wu B; Cheng L; Li F; Zhan Y; Liu C; Ji L; Min Z; Ke Y; Sun L; Chen H; Cheng Y
J Transl Med; 2018 Mar; 16(1):48. PubMed ID: 29499727
[TBL] [Abstract][Full Text] [Related]
10. [Recent progress in immune thrombocytopenia pathophysiology and treatment].
Kato H
Rinsho Ketsueki; 2023; 64(9):1106-1115. PubMed ID: 37899189
[TBL] [Abstract][Full Text] [Related]
11. Cellular immune dysregulation in the pathogenesis of immune thrombocytopenia.
Wen R; Wang Y; Hong Y; Yang Z
Blood Coagul Fibrinolysis; 2020 Mar; 31(2):113-120. PubMed ID: 31977328
[TBL] [Abstract][Full Text] [Related]
12. Current therapeutic strategies and perspectives in refractory ITP: What have we learned recently?
Lv Y; Shi H; Liu H; Zhou L
Front Immunol; 2022; 13():953716. PubMed ID: 36003388
[TBL] [Abstract][Full Text] [Related]
13. Primary and secondary immune thrombocytopenia (ITP): Time for a rethink.
González-López TJ; Provan D; Bárez A; Bernardo-Gutiérrez A; Bernat S; Martínez-Carballeira D; Jarque-Ramos I; Soto I; Jiménez-Bárcenas R; Fernández-Fuertes F
Blood Rev; 2023 Sep; 61():101112. PubMed ID: 37414719
[TBL] [Abstract][Full Text] [Related]
14. Pathophysiology and management of primary immune thrombocytopenia.
Kashiwagi H; Tomiyama Y
Int J Hematol; 2013 Jul; 98(1):24-33. PubMed ID: 23702914
[TBL] [Abstract][Full Text] [Related]
15. Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives.
Vianelli N; Auteri G; Buccisano F; Carrai V; Baldacci E; Clissa C; Bartoletti D; Giuffrida G; Magro D; Rivolti E; Esposito D; Podda GM; Palandri F
Ann Hematol; 2022 May; 101(5):963-978. PubMed ID: 35201417
[TBL] [Abstract][Full Text] [Related]
16. Refractory immune thrombocytopenia in adults: Towards a new definition.
Arnold DM; Clerici B; Ilicheva E; Ghanima W
Br J Haematol; 2023 Oct; 203(1):23-27. PubMed ID: 37642211
[TBL] [Abstract][Full Text] [Related]
17. Myeloid-derived suppressor cells anticipate sustained treatment response in newly-diagnosed and persistent primary immune thrombocytopenia.
Elsaied DG; Noreldin NM; Saad MA; Elkhatteb MA; Esheba NE
Blood Cells Mol Dis; 2021 Mar; 87():102529. PubMed ID: 33338696
[TBL] [Abstract][Full Text] [Related]
18. [Current treatment of primary immune thrombocytopenia].
Lozano ML; Vicente V
Med Clin (Barc); 2014 May; 142(9):399-405. PubMed ID: 23809409
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and significance of large granular lymphocytes in patients with immune thrombocytopenia.
Gabe C; Liu Y; Duncan J; St John M; Lucier KJ; Kimmel D; Kelton JG; Arnold DM
Platelets; 2023 Dec; 34(1):2144194. PubMed ID: 36458562
[TBL] [Abstract][Full Text] [Related]
20. [Diagnostic approach and treatment of immune thrombocytopenia in adults].
Kolonić SO; Patekar MB; Milunović V
Acta Med Croatica; 2013 Mar; 67(1):3-11. PubMed ID: 24279250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
